Skip to content
Comparison

Hexarelin vs Ipamorelin

Hexarelin and Ipamorelin are commonly compared for high-potency GHRP versus selective GHRP use. Hexarelin is usually favored for maximum acute GH pulse intensity, while Ipamorelin is often preferred for better selectivity/tolerability for longer protocols. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For high-potency GHRP versus selective GHRP use, the better choice depends on your primary endpoint. Hexarelin is stronger when the priority is short high-output cycles. Ipamorelin is stronger when the priority is longer cleaner GH optimization plans. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaHexarelinIpamorelin
Primary mechanismPotent nonselective GHRP with CD36-linked cardiac effectsSelective GHS-R1a agonist (GHRP) with lower cortisol/prolactin signal
Strongest clinical signalStrong GH pulses and notable preclinical cardioprotective signalsReliable GH pulse support with cleaner endocrine profile than older GHRPs
Typical dosing context100-200 mcg one to three times daily100-300 mcg, often 1-3 times daily
AdministrationSubcutaneous injectionSubcutaneous injection
Evidence quality gradePreclinical-heavy with limited modern translational dataModerate mechanistic and clinical support
Regulatory statusNot FDA-approvedNot FDA-approved; clinic/research use
Side-effect burdenHigher endocrine spillover and tachyphylaxis riskGenerally mild side effects when appropriately dosed
Cost/access contextModerate peptide-market pricingVariable clinic and compounding pricing
Best candidate profileShort cycles where high GH pulse intensity is prioritizedUsers seeking GH support with fewer appetite/cortisol issues
Main limitationDesensitization and side-effect profile limit durationEvidence depth below approved endocrine therapies
Best use case in this comparisonshort high-output cycleslonger cleaner GH optimization plans

When to Choose Each

Choose Hexarelin

Best for short high-output cycles.

Choose Ipamorelin

Best for longer cleaner GH optimization plans.

Verdict

If the main goal is short high-output cycles, Hexarelin is usually the better first-line choice. If the main goal is longer cleaner GH optimization plans, Ipamorelin is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. Hexarelin, a synthetic growth hormone secretagogue, and cardiac function (1996) — PubMed
  2. Cardiac effects of hexarelin in GH-deficient and healthy subjects: mediation through a specific cardiac receptor (2000) — PubMed
  3. Hexarelin protects the heart from ischemia-reperfusion injury via the CD36 scavenger receptor (2005) — PubMed
  4. Growth hormone secretagogues: cardiovascular effects and therapeutic potential (2007) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Which has stronger evidence for high-potency GHRP versus selective GHRP use — Hexarelin or Ipamorelin?
Hexarelin is graded as preclinical-heavy with limited modern translational data evidence in this context, while Ipamorelin is graded as moderate mechanistic and clinical support. In practice, strength depends on whether you prioritize short high-output cycles or longer cleaner GH optimization plans. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can Hexarelin and Ipamorelin be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next